Noxopharm (ASX:NOX) said BioRay Pharmaceutical found positive results as part of its investigation into the use of Noxopharm's oligonucleotides as targeted drugs in the context of antibody-drug conjugates, according to a Wednesday Australian bourse filing.
The results showed that conjugation to a specific Noxopharm oligonucleotide could be achieved and that the conjugated drug significantly improved the performance of one of BioRay's antibodies designed to target autoimmune disease, further reducing inflammation, represented by a key biological marker.
BioRay plans to conduct further studies with its drugs and Noxopharm's assets.
In 2024, Noxopharm signed a material transfer agreement with BioRay, which is active in China's biopharmaceutical industry.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。